Breaking News

ICON Appoints CMO

July 2, 2013

Buckley brings 30 years of experience

Professor Brendan Buckley has been appointed chief medical officer at ICON plc. Professor Buckley will be ICON’s lead medical expert, representing the company’s position on key scientific, ethical and medical governance matters, as well as provide guidance and oversight to the medical and scientific groups.
Professor Buckley is an endocrinologist with more than 30 years of experience. He joined ICON through the acquisition of Firecrest Clinical in 2011, where he was one of the founders of the company and senior vice president of Medical Affairs. He has extensive experience in clinical trials and chairs several independent Data and Safety Monitoring Boards. Mr. Buckley is Clinical Professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland. 
Ciaran Murray, chief executive officer ICON plc, said, “I would like to congratulate Brendan on his new role and welcome him to ICON’s executive leadership team. Brendan’s wealth of experience both as an advisor to European regulatory agencies and a physician with over 30 years of clinical trial experience, will help us advance our clients' products through their development pipelines and ensure ICON studies continue to be performed to the highest scientific and ethical standards.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important